ANDROGEN deprivation therapy (ADT) which is commonly used to treat prostate cancer, may be associated with an increased risk of dementia, according to new research published in JAMA Oncology.
ADT reduces the levels of androgens which can stimulate the growth of prostate cancer cells, but is now under an associative cloud around neurocognitive dysfunction.
CLICK HERE for the abstract.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Oct 16
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Oct 16
